Tramazol

Quick links to important sections

Tramazol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramazol

Defining Tramazol: A Centrally Acting Analgesic

Property Description
Active Ingredient Tramadol Hydrochloride
Pharmacological Class Centrally Acting Opioid Analgesic
Origin Synthetic Compound
Primary Forms Tablet, Capsule, Solution, Injection
General Use Relief of moderate to moderately severe pain

Tramazol is a prescription medication whose active substance, Tramadol Hydrochloride, is clinically recognized as a synthetic opioid analgesic that acts upon the central nervous system. Its primary general purpose is to provide effective relief for pain categorized as moderate to moderately severe. As an opioid agonist, its mechanism of action works centrally in the brain and spinal cord to relieve discomfort. This means the medication works directly on the central nervous system to reduce the overall perception of pain.


Composition and Available Forms of Tramadol Hydrochloride

The chemical composition of Tramazol relies solely on the active pharmaceutical ingredient, Tramadol Hydrochloride, which is typically manufactured as a racemic mixture of two mirror-image molecules. This medicine is a single-ingredient product, containing only the primary active substance. Due to its Rx-only status, Tramazol is not available over the counter, differentiating it from many non-opioid analgesics.

This key substance is manufactured in multiple pharmaceutical preparations to allow for different administration routes, specifically differentiating forms tailored for intravenous use in hospital settings from oral forms for chronic, outpatient management. These forms include various oral forms, such as immediate-release and extended-release tablets and capsules, as well as solutions for injection or rectal administration. The variety of forms ensures the medicine can be tailored to various patient needs, providing either rapid acute or sustained chronic relief.


The Multimodal Approach to Pain Relief

Tramazol achieves its overall analgesic effect through a unique multimodal mechanism of action that targets pain through two distinct pathways. One pathway involves binding to the mu-opioid receptors, which directly dampens the intensity of pain signals. The second, complementary pathway involves inhibiting the reuptake of the natural neurotransmitters, norepinephrine and serotonin, which helps enhance the body's own descending system for naturally controlling pain. Because it acts on two different pathways, this drug provides a comprehensive approach to managing pain, an approach often utilized for chronic pain conditions. This dual functionality ensures a robust and broad effect for managing complex or persistent pain.

Regulatory References

  1. Tramadol: MedlinePlus Drug Information

What side effects are possible with Tramazol?

Possible Side Effects and Safety Information

The official regulatory safety profile for Tramazol (Tramadol Hydrochloride) provides a structured classification of potential adverse reactions, grouping them by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on incidence observed in regulatory trials and post-marketing data. The most frequently reported effects are classified as Very Common.

Classification Examples of Documented Effects
Very Common (Affects ge 1 in 10) Nausea, Dizziness
Common (Affects ge 1 in 100 to < 1 in 10) Headache, Somnolence, Vomiting, Constipation, Sweating, Dry mouth
Rare (Affects ge 1 in 10,000 to < 1 in 1,000) Convulsions (Seizures), Confusion, Hallucinations

These effects are formally organized into System-Organ Classes, including Gastrointestinal disorders (e.g., Nausea, Constipation), Nervous System disorders (e.g., Dizziness, Convulsions), and Psychiatric disorders (e.g., Confusion).

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly highlight the risk of certain serious adverse reactions. These include potentially life-threatening Respiratory Depression, the risk of Serotonin Syndrome, and the risk of Dependence and addiction, even when used at therapeutic doses. The risk of seizures is also documented and may occur even at recommended doses.

Safety constraints define specific populations where the medicine is contraindicated, such as in children younger than 12 years of age. Regulatory notes also specify that the risk of certain adverse effects, like respiratory depression, is highest during treatment initiation or following a dose increase, and that the risk of physical dependence increases with prolonged use.

Overdose and Emergency Response

Overdose and when to seek help

Immediate emergency medical attention must be sought if an overdose of Tramazol is suspected or confirmed. Overdose can be life-threatening and may result in severe respiratory and central nervous system (CNS) depression.

Documented Overdose Presentations

The most severe and potentially fatal clinical manifestations of Tramazol overdose, as documented in regulatory information, include:

  • Life-threatening respiratory depression (slowed or shallow breathing).
  • Profound sedation leading to coma and death.
  • Seizures (convulsions).
  • Miosis (pinpoint pupils).
  • Hypotension (low blood pressure) and circulatory collapse.

High-Risk Overdose Scenarios

Overdose risk is significantly increased by abuse, misuse, or addiction. Accidental ingestion of even one dose, especially by a child, can result in a fatal overdose. Combining Tramazol with other CNS depressants, such as alcohol or benzodiazepines, also greatly increases the risk of severe respiratory depression and death.

Emergency Action Required

If overdose is suspected, call 911 or emergency services immediately—do not wait for symptoms to worsen. Treatment focuses on re-establishing a patent airway and providing controlled ventilation if necessary. An opioid antagonist such as naloxone may be administered to reverse respiratory depression, though the use of naloxone may increase the risk of seizures.

Therapeutic Uses of Tramazol

What Tramazol Treats: Main Uses and Benefits

Tramazol is commonly used to manage symptoms related to moderate to moderately severe pain in adults.

Relieving Acute Pain and High-Intensity Discomfort

Tramazol is commonly used to help manage symptoms related to acute pain and intense discomfort in situations involving certain distressing symptoms. It is relevant when supportive symptom management is appropriate, providing support that helps ease the overall symptom burden during periods of heightened symptoms.


Managing Symptom Clusters that Disrupt Function

The medication is applied in contexts where additional symptomatic support is needed to address symptom clusters that interfere with daily functioning or create noticeable physiological strain. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, especially when symptoms become more disruptive during flare-ups or acute episodes. This medicine is applied across domains where additional symptomatic support is needed, contributing to improved comfort during symptomatic periods, and supports general well-being during symptomatic phases.


Quick Fact: Relief for Acute and Moderately Severe Pain

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tramazol

The following rules strictly define population eligibility for Tramazol according to official regulatory documents from authorities such as the FDA and EMA.

Category Official Regulatory Statements on Eligibility
Populations for whom use is allowed Adults and Adolescents aged 12 years and older (for standard immediate-release formulations) are generally permitted for use.
Populations for whom use is contraindicated Children younger than 12 years of age are prohibited from use. Contraindication also applies to adolescents under 18 following tonsillectomy or adenoidectomy [FDA]. Use is prohibited in patients with known hypersensitivity to tramadol, significant respiratory depression, or acute intoxication with central nervous system depressants.
Condition-specific eligibility rules The medicine is contraindicated in patients with uncontrolled epilepsy and known or suspected gastrointestinal obstruction [SmPC]. Use must be approached with caution in patients with a history of substance abuse or those who are opioid-dependent.
Organ Function and Age Restrictions Severe renal impairment or severe hepatic impairment renders use of extended-release formulations not recommended [FDA]. Patients over 75 years of age should be treated with caution.
Pregnancy and lactation eligibility Use is not recommended for pregnant women due to the risk of Neonatal Opioid Withdrawal Syndrome [FDA]. Nursing mothers are also not recommended to use the drug.

Connection to the overall eligibility profile: The regulatory profile establishes definitive boundaries for patient selection. It formally excludes populations based on age and pre-existing physiological risks, using classifications like Contraindicated (absolute prohibition) and Not Recommended (strong avoidance advised), ensuring compliance with documented safety mandates.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tramazol is associated with significant drug interactions that can lead to serious adverse effects due to its dual mechanism of action as an opioid agonist and a reuptake inhibitor of norepinephrine and serotonin.

High-Risk Combinations

Interacting Product Category Potential Effect Severity Classification
Monoamine Oxidase Inhibitors (MAOIs) (e.g., phenelzine, linezolid) May lead to Serotonin Syndrome or seizures. Contraindicated (Must not be used concurrently or within 14 days of stopping an MAOI).
CNS Depressants (including alcohol, benzodiazepines, other opioids) Risk of profound sedation, respiratory depression, coma, and death. Serious Risk/Boxed Warning (Use should be avoided or limited to the lowest dose for the shortest duration necessary).
Serotonergic Drugs (e.g., SSRIs, SNRIs, Triptans, St. John's Wort) Increased risk of Serotonin Syndrome, a potentially life-threatening condition. Caution/Monitor Closely (Requires vigilant monitoring for symptoms).

Metabolism-Based Interactions

Tramazol is metabolized primarily by the CYP2D6 and CYP3A4 liver enzymes. Co-administration with other drugs that affect these enzymes can alter Tramazol's concentration and the level of its active metabolite (M1), thereby affecting both efficacy and safety.

  • CYP3A4 Inducers (e.g., Carbamazepine): These may increase Tramazol metabolism, which can significantly reduce the analgesic effect. Concomitant use with Carbamazepine is generally not recommended.
  • CYP2D6 Inhibitors (e.g., quinidine, fluoxetine): These may increase Tramazol levels but decrease the active M1 metabolite, potentially reducing efficacy and increasing seizure risk.

Patients should avoid using Tramazol with other tramadol-containing products, and use with mixed agonist/antagonist opioids (e.g., butorphanol) should be avoided as they may reduce Tramazol's pain-relieving effects or precipitate withdrawal.

Mechanism of Action

How Tramazol Works

Tramazol acts as a selective inhibitor, primarily targeting the enzyme Matrix Metalloproteinase-13 ( MMP-13). The compound achieves its effect by accumulating selectively within the joint tissue and binding reversibly to the active site of the MMP-13 catalytic domain. This specific molecular interaction directly reduces the enzyme’s proteolytic activity.

Inhibition of MMP-13 initiates a downstream intracellular cascade that limits the enzymatic cleavage of Type II collagen and other key structural proteins within the extracellular matrix. By modifying this catabolic process, Tramazol influences the fundamental biochemical balance between matrix degradation and synthesis. This targeted pharmacodynamic action modulates systemic physiological turnover processes at the cellular level without expressing agonist activity.

Dosage and Administration Information

Tramazol is administered according to standard specifications that define its administration route, dosage limits, and frequency. The medicine is used via the oral route as Immediate-Release (IR) or Extended-Release (ER) formulations, and via the parenteral route as a solution for Intravenous (IV) or Intramuscular (IM) injection.

Standard adult dosing regimens are based on the release profile. The IR forms are typically prescribed for administration every 4 to 6 hours as needed, with the total daily dose limited to 400 mg. In contrast, the ER forms are intended for once-daily use, typically starting at 100 mg, with a lower maximum daily limit of 300 mg.

Usage instructions provide that extended-release tablets and capsules are to be swallowed whole and are not to be crushed, chewed, or divided. Furthermore, when taking the ER formulation, a consistent administration schedule relative to food intake is maintained.

Clinical protocols provide that Tramazol be used for the shortest possible duration. Specific adjustments to the standard regimen are used for certain populations: the dosing interval is extended and the maximum dose reduced for older adults and patients with severe renal or hepatic impairment. Finally, the dose is tapered gradually upon cessation to align with discontinuation guidelines.

Recent Clinical Evidence

Evidence for use in Acute Pain (Moderate to Moderately Severe)

Acute pain studies involved short-term randomized controlled trials (RCTs), where the medicine was evaluated in adult patients with time-limited discomfort, such as following surgical procedures. These studies explored outcomes like pain intensity scores and patient-reported outcomes describing perceived discomfort.

These studies monitored outcomes over very short time intervals, mainly focusing on the immediate, short-term period. Studies report patterns observed in measured pain scores and patient ratings. Research contributes to understanding these short-term changes, but follow-up durations were limited. There is limited information for long-term outcomes beyond the immediate observation windows.


Evidence for use in Chronic Pain (Moderate to Moderately Severe)

The research examined chronic conditions such as osteoarthritis and diabetic neuropathic pain using systematic reviews and meta-analyses. Studies explored outcomes related to daily functioning and patient-reported discomfort over defined intervals. Findings describe patterns observed in these studies, which generally lasted up to 12 weeks.

Some reviews indicate that observed changes were sometimes small when compared to what patients typically report as a meaningful difference. Findings were mixed regarding functional measures, and evidence quality varies across the research base. Because follow-up durations were limited (up to 12 weeks is short for chronic conditions), the research provides context but not individual predictions about the potential for sustained changes.


Evidence in Special Populations and Research Uncertainty

Evidence in special populations includes studies in older adults (aged 65 years and above) with chronic conditions, but evidence is limited for long-term use in this group. For pediatric patients (children), the research describes differences observed in the way the medicine was studied compared to adults, and data for certain groups remain insufficient to draw broad conclusions.

Overall, the research landscape has known limitations. Sample sizes were modest in many controlled trials, and follow-up durations were limited for chronic management. There is limited information for long-term outcomes, particularly regarding sustained effects on functional status. Comparative evidence is lacking between this medicine and several other non-opioid options in controlled trials.

Frequently Asked Questions (FAQ)

Common questions about Tramazol (FAQ)


Q: How quickly does Tramazol usually start working?

A: According to official product information, the Immediate-Release (IR) form of this medicine typically begins to relieve discomfort within one hour of administration. The time to reach peak concentrations in the body is generally described as two to three hours after a dose.


Q: What is the typical duration of Tramazol's effect?

A: The expected duration of the medicine's effect is consistent with the standard interval for administration, which is typically described as every four to six hours. The dosing frequency is defined in the official regulatory documents.


Q: Does Tramazol cause weight gain or weight loss?

A: Official regulatory documents list 'weight decrease' as an infrequent adverse reaction, meaning it is rarely reported in clinical settings. Weight gain is not listed among the commonly reported side effects in the official safety profile.


Q: Can Tramazol affect my sleep?

A: Official safety information indicates that the medicine may affect sleep patterns. Regulatory documents list Somnolence (drowsiness or feeling sleepy) as a Common side effect, and Insomnia (difficulty falling or staying asleep) as a less frequent adverse reaction.


Q: Is it common to feel dizzy after taking Tramazol?

A: Yes, Dizziness is listed in the official safety profile as a Very Common side effect. This classification means it is reported in 1 in 10 or more people who use the medicine.


Q: What should I do if I forget to take a dose of Tramazol?

A: Official instructions advise that the user typically skips the missed dose and returns to their regular schedule. The guidance is to avoid taking two doses at the same time to make up for a missed dose.


Q: Can I drive or operate machinery after taking Tramazol?

A: Official regulatory warnings advise that this medicine may impair the mental and physical abilities required for potentially dangerous tasks. Activities that may be affected include driving a car or operating heavy machinery.


Q: Can Tramazol be crushed or split?

A: The Extended-Release (ER) formulations are officially required to be swallowed whole and must not be split, chewed, or crushed. This is mandated because crushing the tablet can compromise the extended-release feature and significantly increase the rate of medicine absorption.


Q: Can Tramazol affect birth control pills?

A: Tramazol is processed by specific liver enzymes. While official labels do not explicitly highlight a significant interaction with oral contraceptives, the overall interaction profile suggests that the use of this medicine with any hormonal birth control should be discussed with a healthcare provider.


Q: Does taking Tramazol affect my mood or behavior?

A: The official safety profile includes possible effects on mood and behavior. Less frequent side effects listed under Psychiatric Disorders include confusion, hallucinations, and changes in mood (e.g., euphoria or dysphoria).


Q: Is Tramazol considered a pain medication?

A: Yes, according to US regulatory documents, this medicine is officially classified as a centrally acting opioid analgesic. Its purpose is described as the management of moderate to moderately severe pain.


Q: Is it okay to take Tramazol for a long time?

A: Regulatory guidance emphasizes that the medicine should be used for the shortest possible duration. Official warnings note that the risk of physical dependence and addiction is known to increase with prolonged use.


Q: Can I take Tramazol if I'm already taking supplements?

A: The official drug interaction list includes the herbal remedy St. John's Wort, noting that it may increase the risk of Serotonin Syndrome. Due to its metabolic profile, users are generally advised to inform a healthcare professional about all supplements being taken.


Q: Are there any common foods or drinks that interact with Tramazol?

A: Official documents carry a warning against using this medicine with alcohol due to the severe risk of profound sedation, respiratory depression, and other serious effects. For the extended-release forms, official guidance advises maintaining a consistent administration schedule relative to food intake.


Q: What does it mean that Tramazol is a 'schedule' drug?

A: It means the medicine is classified as a Controlled Substance (Schedule IV) by US federal regulation. This classification is given due to the medicine's potential for abuse, misuse, and physical dependence.


Q: Why might a doctor prescribe Tramazol instead of another option?

A: Official descriptions highlight the medicine’s unique dual mechanism of action. Its dual action on opioid receptors and neurotransmitter reuptake establishes it as a pharmacological option for moderate to moderately severe pain.


Q: Is Tramazol habit-forming or addictive?

A: Official regulatory documents include a serious Boxed Warning that the medicine exposes users to the risks of addiction, abuse, and misuse. These risks are noted in regulatory warnings even when the medicine is used as prescribed.


Q: How is Tramazol different from [Name of a common similar drug]?

A: The main distinction noted in official descriptions is its multimodal mechanism of action. It achieves its effect through two distinct pathways: binding to mu-opioid receptors and inhibiting the reuptake of norepinephrine and serotonin. This dual action is a key property of the medicine.


Q: What kind of studies have been done on Tramazol?

A: The research evidence base includes short-term randomized controlled trials (RCTs) for acute pain and systematic reviews or meta-analyses for chronic conditions. Studies have also been conducted in special populations such as older adults.


Q: What are the official restrictions on who can use Tramazol?

A: Official restrictions formally contraindicate the medicine for several groups to prevent serious harm. These groups include children younger than 12 years of age, patients with significant respiratory depression, and those experiencing acute intoxication from central nervous system depressants.


Q: Why do some people say Tramazol didn't work for them?

A: Clinical trial reports indicate that for chronic pain conditions, the observed changes were sometimes small when compared to what patients consider a meaningful difference. The official research reports that the quality and findings of effectiveness evidence vary across the studies.


Q: What are the signs that Tramazol is actually working?

A: Clinical studies evaluate the effectiveness of the medicine using measurable outcomes. These outcomes include objective measures like reduced pain intensity scores and subjective results like patient-reported outcomes describing perceived discomfort.


Q: Is Tramazol only for short-term use?

A: Official regulatory documents state that the medicine should be used for the shortest possible duration. While research does cover chronic conditions, studies often have limited follow-up periods, and the risk of dependence increases with prolonged use.


Q: Are there specific symptoms that mean I should call a doctor immediately?

A: Official safety warnings highlight the risk of serious adverse reactions, including Serotonin Syndrome, Respiratory Depression, and Convulsions (Seizures). Symptoms associated with these serious conditions are identified as requiring immediate medical attention.


Q: Does Tramazol affect blood sugar levels?

A: While not listed as a common side effect in trials, post-marketing reports have indicated an association between use of the medicine and the development of hypoglycemia (low blood sugar). This information is officially noted by some regulatory bodies.


Q: Can Tramazol be used by people who have certain heart conditions?

A: Regulatory documents require caution in patients with underlying medical conditions. The medicine is officially noted to potentially cause Severe Hypotension (low blood pressure), which may require careful monitoring when used by patients with pre-existing heart conditions.


Q: What is the common reason people stop taking Tramazol?

A: Official research reports indicate that patients in clinical trials were more likely to withdraw from the study due to adverse events (side effects) than those taking non-opioid pain relief options. This suggests side effects are a common reason for discontinuation.


Q: Can Tramazol make me feel tired or drowsy?

A: Yes, the official safety information lists Somnolence (drowsiness or feeling tired) as a Common side effect. Since this affects at least 1 in 100 people, it is a frequently reported experience.


Q: Is it possible to develop a tolerance to Tramazol over time?

A: Yes, regulatory documents indicate that continuous use, similar to other opioid analgesics, may lead to the development of tolerance (a need for higher doses to achieve the same effect) and physical dependence.


Q: Does Tramazol interact with common cold or flu medicines?

A: Because Tramazol interacts with both CNS depressants and serotonergic drugs, regulatory caution is advised. Users should be aware of all ingredients in common cold or flu products before using them with this medicine.


Q: 'Tramazol' is the brand name or the generic name?

A: The official active ingredient for this medicine is Tramadol Hydrochloride. This is the generic name, which is available under various brand names, though 'Tramazol' is a general, non-proprietary term used for description.

How should Tramazol be stored and disposed of?

Storage and Disposal of Tramazol

Tramadol Hydrochloride tablets must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with temporary excursions permitted. The medicine must be kept in its original container and protected from heat, moisture, and freezing.

Child Safety and Security

Due to the significant risk of fatal accidental overdose, Tramadol must be stored securely, out of the sight and reach of children and in a location not accessible by others.

Disposal Instructions

Unused or expired Tramadol should be disposed of promptly. The best option is to use an official drug take-back program. If a take-back site is not readily available, regulatory guidance includes Tramadol on the Flush List, advising immediate flushing down the toilet to prevent accidental ingestion, especially by children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tramazol found in:

A-Z Index: